Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-05-20

Clinical Trial Update: XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating XELOX in advanced biliary tract carcinoma after failure of gemcitabine-based chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Samsung Medical Center | Conditions: Biliary Tract Cancer | Phase 2 | Status: UNKNOWN